Prevention and treatment of variceal haemorrhage in 2017

Liver International

Volumn 37, Issue , 2017, Pages 104-115

  Brunner, Felix ^a   Berzigotti, Annalisa ^a   Bosch, Jaime ^a,b  

^a UNIVERSITY OF BERN   (Switzerland)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

cirrhosis; portal hypertension; variceal bleeding; varices

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIBIOTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CARVEDILOL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EMRICASAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LONG ACTING DRUG; NEW DRUG; OBETICHOLIC ACID; SIMTUZUMAB; SOMATOSTATIN DERIVATIVE; TERLIPRESSIN; VASOACTIVE AGENT; VASOCONSTRICTOR AGENT; ANTIINFECTIVE AGENT; CARBAZOLE DERIVATIVE; PROPANOLAMINE DERIVATIVE;

ANTIBIOTIC THERAPY; ASCITES; DISEASE COURSE; ENDOSCOPIC THERAPY; ESOPHAGEAL STENT; ESOPHAGEAL TAMPONADE; ESOPHAGUS DISEASE; ESOPHAGUS VARICES BLEEDING; HEPATIC ENCEPHALOPATHY; HIGH RISK PATIENT; HUMAN; INTERVENTIONAL RADIOLOGY; LIVER CIRRHOSIS; LIVER FIBROSIS; NONHUMAN; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RESUSCITATION; REVIEW; RISK FACTOR; SELF EXPANDABLE METALLIC STENT; STOMACH VARICES; STOMACH VARICES BLEEDING; SURVIVAL; TRANSJUGULAR INTRAHEPATIC PORTOSYSTEMIC SHUNT; TREATMENT FAILURE; BALLOON OCCLUSION; COMPLICATION; ENDOSCOPY; ESOPHAGUS VARICES; GASTROINTESTINAL HEMORRHAGE; RECURRENT DISEASE; SECONDARY PREVENTION;

ADRENERGIC BETA-ANTAGONISTS; ANTI-BACTERIAL AGENTS; BALLOON OCCLUSION; CARBAZOLES; ENDOSCOPY; ESOPHAGEAL AND GASTRIC VARICES; GASTROINTESTINAL HEMORRHAGE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION, PORTAL; LIVER CIRRHOSIS; PORTASYSTEMIC SHUNT, TRANSJUGULAR INTRAHEPATIC; PROPANOLAMINES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION;

EID: 85007579397     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.13277     Document Type: Review

References (55)

1. Bosch J, Abraldes JG, Berzigotti A, et al. The clinical use of HVPG measurements in chronic liver disease. Nat Rev Gastroenterol Hepatol. 2009;6:573–582.
2. Ripoll C, Groszmann R, Garcia-Tsao G, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007;133:481–488.
3. Kovalak M, Lake J, Mattek N, et al. Endoscopic screening for varices in cirrhotic patients: data from a national endoscopic database. Gastrointest Endosc. 2007;65:82–88.
4. Merli M, Nicolini G, Angeloni S, et al. Incidence and natural history of small esophageal varices in cirrhotic patients. J Hepatol. 2003;38:266–272.
5. Groszmann RJ, Garcia-Tsao G, Bosch J, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005;353:2254–2261.
6. The North Italian Endoscopic Club for the Study, Treatment of Esophageal Varices. Prediction of the first variceal hemorrhage in patients with cirrhosis of the liver and esophageal varices. A prospective multicenter study. N Engl J Med. 1988;319:983–989.
7. Garcia-Tsao G, Bosch J. Management of varices and variceal hemorrhage in cirrhosis. N Engl J Med. 2010;362:823–832.
8. Carbonell N, Pauwels A, Serfaty L, et al. Improved survival after variceal bleeding in patients with cirrhosis over the past two decades. Hepatology. 2004;40:652–659.
9. European Association for the Study of the Liver, Asociacion Latinoamericana para el Estudio del Higado. EASL-ALEH clinical practice guidelines: non-invasive tests for evaluation of liver disease severity and prognosis. J Hepatol. 2015;63:237–264.
10. de Franchis R. Expanding consensus in portal hypertension. J Hepatol. 2015;63:743–752.
11. Berzigotti A, Seijo S, Arena U, et al. Elastography, spleen size, and platelet count identify portal hypertension in patients with compensated cirrhosis. Gastroenterology. 2013;144:102–111.
12. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006;44:217–231.
13. D'Amico G, Pasta L, Morabito A, et al. Competing risks and prognostic stages of cirrhosis: a 25-year inception cohort study of 494 patients. Aliment Pharmacol Ther. 2014;39:1180–1193.
14. Bosch J, Groszmann RJ, Shah VH. Evolution in the understanding of the pathophysiological basis of portal hypertension: how changes in paradigm are leading to successful new treatments. J Hepatol. 2015;62(S1):S121–S130.
15. Calés P, Oberti F, Payen JL, et al. Lack of effect of propranolol in the prevention of large oesophageal varices in patients with cirrhosis. Eur J Gastroenterol Hepatol. 1999;11:741–745.
16. Lebrec D, Poynard T, Hillon P, et al. Propranolol for prevention of recurrent gastrointestinal bleeding in patients with cirrhosis. N Engl J Med. 1981;305:1371–1374.
17. Poynard T, Calès P, Pasta L, et al. Beta-adrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. N Engl J Med. 1991;324:1532–1538.
18. Senzolo M, Cholongitas E, Burra P, et al. Beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009;29:1189–1193.
19. Garcia-Pagan JC, Navasa M, Bosch J, et al. Enhancement of portal pressure reduction by the association of isosorbide-5-mononitrate to propranolol administration in patients with cirrhosis. Hepatology. 1990;11:230–238.
20. Bureau C, Péron J-M, Alric JL, et al. ‘A La Carte’ treatment of portal hypertension: adapting medical therapy to hemodynamic response for the prevention of bleeding. Hepatology. 2002;36:1361–1366.
21. García-Pagán JC. Propranolol plus placebo versus propranolol plus isosorbide-5-mononitrate in the prevention of a first variceal bleed: a double-blind RCT. Hepatology. 2003;37:1260–1266.
22. Sinagra E, Perricone G, D'Amico M, et al. Systematic review with meta-analysis: the haemodynamic effects of carvedilol compared with propranolol for portal hypertension in cirrhosis. Aliment Pharmacol Ther. 2014;39:557–568.
23. Reiberger T, Ulbrich G, Ferlitsch A, et al. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013;62:1634–1641.
24. Tripathi D, Ferguson JW, Kochar N, et al. Randomized controlled trial of carvedilol versus variceal band ligation for the prevention of the first variceal bleed. Hepatology. 2009;50:825–833.
25. Berzigotti A, Bosch J. Pharmacologic management of portal hypertension. Clin Liver Dis. 2014;18:303–317.
26. Wiest R, Tsai MH, Groszmann RJ. Octreotide potentiates PKC-dependent vasoconstrictors in portal- hypertensive and control rats. Gastroenterology. 2001;120:975–983.
27. Cirera I, Feu F, Luca A, et al. Effects of bolus injections and continuous infusions of somatostatin and placebo in patients with cirrhosis: a double-blind hemodynamic investigation. Hepatology. 1995;22:106–111.
28. Abraldes JG, Bosch J. Somatostatin and analogues in portal hypertension. Hepatology. 2002;35:1305–1312.
29. Abraldes JG, Albillos A, Bañares R, et al. Simvastatin lowers portal pressure in patients with cirrhosis and portal hypertension: a randomized controlled trial. Gastroenterology. 2009;136:1651–1658.
30. Abraldes JG, Villanueva C, Aracil C, et al. Addition of simvastatin to standard therapy for the prevention of variceal rebleeding does not reduce rebleeding but increases survival in patients with cirrhosis. Gastroenterology. 2016;150:1160–1170.e3.
31. Mohanty A, Tate JP, Garcia-Tsao G. Statins are associated with a decreased risk of decompensation and death in veterans with hepatitis C-related compensated cirrhosis. Gastroenterology 2016;150:430–440.e1.
32. Tandon P, Abraldes JG, Berzigotti A, et al. Renin-angiotensin-aldosterone inhibitors in the reduction of portal pressure: a systematic review and meta-analysis. J Hepatol. 2010;53:273–282.
33. Markham A, Keam SJ. Obeticholic acid: first global approval. Drugs. 2016;76:1221–1226.
34. Meissner EG, McLaughlin M, Matthews L, et al. Simtuzumab treatment of advanced liver fibrosis in HIV and HCV-infected adults: results of a 6-month open-label safety trial. Liver Int. 2016 May 27. doi: 10.1111/liv.13177. [Epub ahead of print]
35. Garcia-Tsao G, Fuchs M, Shifman ML, et al. Emricasan (IDN-6556) administered orally for 28 days lowers portal pressure in patients with compensated cirrhosis and severe portal hypertension. AASLD 2015. Hepatology. 2015;62(6 Suppl):1379–1399.
36. Dai C, Liu WX, Jiang M, et al. Endoscopic variceal ligation compared with endoscopic injection sclerotherapy for treatment of esophageal variceal hemorrhage: a meta-analysis. World J Gastroenterol. 2015;21:2534–2541.
37. Smith MR, Tidswell R, Tripathi D. Outcomes of endoscopic human thrombin injection in the management of gastric varices. Eur J Gastroenterol Hepatol. 2014;26:846–852.
38. Bureau C, Garcia-Pagan JC, Layrargues GP, et al. Patency of stents covered with polytetrafluoroethylene in patients treated by transjugular intrahepatic portosystemic shunts: long-term results of a randomized multicentre study. Liver Int. 2007;27:742–747.
39. Riggio O, Angeloni S, Salvatori FM, et al. Incidence, natural history, and risk factors of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt with polytetrafluoroethylene-covered stent grafts. Am J Gastroenterol. 2008;103:2738–2746.
40. Park JK, Saab S, Kee ST, et al. Balloon-occluded retrograde transvenous obliteration (BRTO) for treatment of gastric varices: review and meta-analysis. Dig Dis Sci. 2015;60:1543–1553.
41. Garcia-Tsao G, Bosch J. Varices and variceal hemorrhage in cirrhosis: a new view of an old problem. Clin Gastroenterol Hepatol. 2015;13:2109–2117.
42. Tsochatzis EA, Bosch J, Burroughs AK. Future treatments of cirrhosis. Expert Rev Gastroenterol Hepatol. 2014;8:571–581.
43. Villanueva C, Colomo A, Bosch A, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013;368:11–21.
44. Bernard B, Grangé JD, Khac EN, et al. Antibiotic prophylaxis for the prevention of bacterial infections in cirrhotic patients with gastrointestinal bleeding: a meta-analysis. Hepatology. 1999;29:1655–1661.
45. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19:475–505.
46. Seo YS, Park SY, Kim MY, et al. Lack of difference among terlipressin, somatostatin, and octreotide in the control of acute gastroesophageal variceal hemorrhage. Hepatology. 2014;60:954–963.
47. García-Pagán JC, Caca K, Bureau C, et al. Early use of tips in patients with cirrhosis and variceal bleeding for the early TIPS (Transjugular Intrahepatic Portosystemic Shunt) Cooperative Study Group. N Engl J Med. 2010;362:2370–2379.
48. Garcia-Pagán JC, Di Pascoli M, Caca K, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013;58:45–50.
49. McCarty TR, Njei B. Self-expanding metal stents for acute refractory esophageal variceal bleeding: a systematic review and meta-analysis. Dig Endosc 2016;28(5):539–47.
50. Escorsell À, Pavel O, Cardenas A, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: a multicenter randomized, controlled trial. Hepatology. 2016;63:1957–1967.
51. Puente A, Hernandez-Gea V, Graupera I, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int. 2014;34:823–833.
52. D'Amico G, Garcia-Pagan JC, Luca A, et al. Hepatic vein pressure gradient reduction and prevention of variceal bleeding in cirrhosis: a systematic review. Gastroenterology. 2006;131:1611–1624.
53. Holster IL, Tjwa ETTL, Moelker A, et al. Covered transjugular intrahepatic portosystemic shunt versus endoscopic therapy+beta-blocker for prevention of variceal rebleeding. Hepatology. 2016;63:581–589.
54. Sauerbruch T, Mengel M, Dollinger M, et al. Prevention of rebleeding from esophageal varices in patients with cirrhosis receiving small-diameter stents versus hemodynamically controlled medical therapy. Gastroenterology. 2015;149:660–8.e1.
55. Sarin SK. Long-term follow-up of gastric variceal sclerotherapy: an eleven-year experience. Gastrointest Endosc. 1997;46:8–14.